GlassScriptPhysician profile
Ehab Zekri
NPI 1295306280
$4,347.66
in general payments reported to CMS, 2019-2025
30 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.08 · 2023: $827 · 2024: $1,659 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,322.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $645.97 | 2024-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $544.05 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $449.79 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $368.60 | 2023-2025 | |
| Corcept Therapeutics | $301.25 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $295.26 | 2023-2025 | |
| Kyowa Kirin, INC. | $229.21 | 2023-2025 | Crysvita |
| Xeris Pharmaceuticals, INC. | $151.24 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $129.27 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Abbott Laboratories | $115.00 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.61 | 2024-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $103.04 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $81.67 | 2023-2025 | Nexletol |
| Medtronic, INC. | $80.30 | 2025 | Minimed 780g, Intellis Adaptivestim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $78.64 | 2024-2025 | Farxiga |
| Madrigal Pharmaceuticals | $72.88 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $65.96 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $63.23 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $57.18 | 2023-2024 | Strensiq |
| Dexcom, INC. | $56.60 | 2024-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $45.36 | 2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $29.12 | 2025 | Yorvipath |
| Glaxosmithkline, LLC. | $26.35 | 2025 | Shingrix |
| Amryt Pharma Holdings LTD | $25.08 | 2022 | |
| Rgh Enterprises LLC | $24.97 | 2025 | |
| Tolmar, INC. | $24.29 | 2025 | Jatenzo |
| Sequel Med Tech, LLC | $20.34 | 2025 | Twiist |
| Abbvie INC. | $19.16 | 2025 | |
| Cequr Corporation | $6.24 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Zekri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.